ECSP13012416A - Derivados heterocíclicos fusionados como moduladores s1p - Google Patents
Derivados heterocíclicos fusionados como moduladores s1pInfo
- Publication number
- ECSP13012416A ECSP13012416A ECSP13012416A ECSP13012416A EC SP13012416 A ECSP13012416 A EC SP13012416A EC SP13012416 A ECSP13012416 A EC SP13012416A EC SP13012416 A ECSP13012416 A EC SP13012416A
- Authority
- EC
- Ecuador
- Prior art keywords
- optionally substituted
- alkyl
- atoms
- halogen
- substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- -1 amino, dimethylamino Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 239000004305 biphenyl Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con un derivado heterocíclico fusionado de la fórmula (I) (I)en dondeR1 se selecciona de ciano, alquenilo (C 2-4), alquinilo (C 2-4), alquilo (C 1-4), cada uno opcionalmente sustituido con CN o uno o más átomos de flúor, cicloalquilo (C 3-6), cicloalquenilo (C 4-6) o un grupo bicíclico (C 8-10), cada uno opcionalmente sustituido con halógeno o alquilo (C 1-4) opcionalmente sustituido con uno o más átomos de flúor,fenilo, bifenilo, naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, ciano, alquilo (C 1-4) opcionalmente sustituido con uno o más átomos de flúor, alcoxi (C 1-4) opcionalmente sustituido con uno o más átomos de flúor, amino, dimetilamino, y cicloalquilo (C 3-6) opcionalmente sustituido con fenilo que se puede sustituir con alquilo (C 1-4) o halógeno, yfenilo sustituido con fenoxi, bencilo, benciloxi, feniletilo o heterociclo monocíclico, cada uno opcionalmente sustituido con alquilo (C 1-4), Z es un grupo de enlace -W-(alquileno Cn)-T- en donde W se adhiere a R1 y se selecciona de un enlace, -O-, -CO-, -S-, -SO-, -SO2-, -NH-, -CH=CH-, -C(CF3)=CH-, -C?C-, -CH2-O-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO- y trans-ciclopropileno; n es un entero de 0 a 10; y T se adhiere al grupo funcional fenileno/ piridilo y se selecciona de un enlace, -O-, -S-, -SO-, -SO2-, -NH-, -CO-, -C=C-, -C?C-, y trans-ciclopropileno;R2 es H o uno o más sustituyentes seleccionados independientemente de ciano, halógeno, alquilo (C 1-4) opcionalmente sustituido con uno o más átomos de halógeno, o alcoxi (C 1-4) opcionalmente sustituido con uno o más átomos de halógeno;la estructura del anillo A puede contener un átomo de nitrógeno;X se selecciona de C o N; si X es C, R3 se selecciona de H y alquilo (C 1-4), de otra forma R3 no está presente;Y se selecciona de NH, O y S;la estructura Q es una amina cíclica de 5, 6 o 7 miembros; R4 es alquileno (C 1-4)-R5 en donde uno o más átomos de carbono en el grupo alquileno se pueden sustituir independientemente con uno o más átomos de halógeno o con (CH2)2 para formar un grupo funcional ciclopropilo, o R4 es cicloalquileno (C 3-6)-R5, -CH2-cicloalquileno (C 3-6)-R5, cicloalquileno (C 3-6)-CH2-R5 o -CO-CH2-R5, en donde R5 es -OH, -PO3H2, -OPO3H2, -COOH, -COOalquilo (C 1-4) o tetrazol -5- ilo;o una sal farmacéuticamente aceptable, un solvato o hidrato del mismo o uno o más N- óxidos del mismo.Los compuestos de la invención tienen afinidad con los receptores S1P y se puedan utilizar en el tratamiento, alivio o prevención de enfermedades y afecciones en las que (cualquier) receptor (es) S1P está (están) involucrados o en las que está involucrada la modulación del sistema de señalización S1P endógeno a través de cualquier receptor S1P.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36278410P | 2010-07-09 | 2010-07-09 | |
| EP10169107 | 2010-07-09 | ||
| US201161446541P | 2011-02-25 | 2011-02-25 | |
| EP11156007 | 2011-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012416A true ECSP13012416A (es) | 2013-03-28 |
Family
ID=44358260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012416 ECSP13012416A (es) | 2010-07-09 | 2013-02-04 | Derivados heterocíclicos fusionados como moduladores s1p |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8796262B2 (es) |
| EP (1) | EP2590980B1 (es) |
| JP (1) | JP5973429B2 (es) |
| KR (1) | KR101889694B1 (es) |
| CN (1) | CN103068827B (es) |
| AR (1) | AR082136A1 (es) |
| AU (1) | AU2011275755B2 (es) |
| BR (1) | BR112013000627B1 (es) |
| CA (1) | CA2804137C (es) |
| CL (1) | CL2013000069A1 (es) |
| CO (1) | CO6670577A2 (es) |
| CR (1) | CR20130056A (es) |
| DO (1) | DOP2013000009A (es) |
| EC (1) | ECSP13012416A (es) |
| ES (1) | ES2653682T3 (es) |
| IL (1) | IL224054A (es) |
| MX (1) | MX2013000360A (es) |
| MY (1) | MY161229A (es) |
| NZ (1) | NZ605491A (es) |
| PE (1) | PE20130592A1 (es) |
| PH (1) | PH12013500004A1 (es) |
| RU (1) | RU2576660C2 (es) |
| SG (1) | SG186952A1 (es) |
| TW (1) | TWI522361B (es) |
| UY (1) | UY33496A (es) |
| WO (1) | WO2012004373A1 (es) |
| ZA (1) | ZA201300157B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| JP2016011257A (ja) * | 2012-10-23 | 2016-01-21 | 大日本住友製薬株式会社 | テトラヒドロオキサゾロピリジン誘導体 |
| CA2996741A1 (en) | 2015-08-28 | 2017-03-09 | Udo Lange | Fused heterocyclic compounds as s1p modulators |
| WO2018083171A1 (en) | 2016-11-02 | 2018-05-11 | AbbVie Deutschland GmbH & Co. KG | Spiro-compounds as s1p modulators |
| US20210139503A1 (en) * | 2019-10-31 | 2021-05-13 | ESCAPE Bio, Inc. | Processes for preparing an s1p-receptor modulator |
| JP2022553802A (ja) * | 2019-10-31 | 2022-12-26 | エスケープ・バイオ・インコーポレイテッド | Ｓ１ｐ受容体モジュレーターの固体形態 |
| CN115279740B (zh) * | 2020-03-04 | 2025-02-28 | 南昌弘益药业有限公司 | 苯并2-氮杂螺[4.4]壬烷类化合物及其应用 |
| CN117362316A (zh) * | 2023-10-07 | 2024-01-09 | 康龙化成手性医药技术(宁波)有限公司 | 一种四氢吡咯并噻唑类化合物的合成方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1069387A1 (ru) | 1982-07-01 | 1985-11-30 | Институт физико-органической химии и углехимии АН УССР | Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием |
| GB2228432A (en) | 1989-01-13 | 1990-08-29 | Grayston Central Services | Multi-role machine for heating and coating pipe welds. |
| JPH03206042A (ja) * | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
| JP2681589B2 (ja) | 1992-12-28 | 1997-11-26 | 日揮株式会社 | 配管溶接継手の熱処理方法 |
| JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
| GB9522845D0 (en) | 1995-11-08 | 1996-01-10 | Smithkline Beecham Plc | Novel compounds |
| JP3822680B2 (ja) | 1996-08-30 | 2006-09-20 | 新日本製鐵株式会社 | 誘導加熱された接合部の冷却方法および冷却装置 |
| JP3974781B2 (ja) | 2000-04-21 | 2007-09-12 | 塩野義製薬株式会社 | 抗癌作用を有するオキサジアゾール誘導体 |
| FR2822727A1 (fr) | 2001-04-03 | 2002-10-04 | Gesal Ind | Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement |
| JP3649223B2 (ja) | 2003-01-08 | 2005-05-18 | 株式会社日立製作所 | 配管系の熱処理方法および熱処理装置 |
| CA2512546A1 (en) * | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CA2526209A1 (en) | 2003-06-12 | 2004-12-23 | Btg International Limited | Cyclic hydroxylamine as psychoactive compounds |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| AP2006003771A0 (en) | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| NZ550891A (en) * | 2004-06-30 | 2009-10-30 | Athersys Inc | Substituted azepine derivatives as serotonin receptor modulators |
| WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| JP4491334B2 (ja) | 2004-12-01 | 2010-06-30 | 日立Ｇｅニュークリア・エナジー株式会社 | 配管の熱処理方法および装置 |
| JP4599250B2 (ja) | 2005-08-10 | 2010-12-15 | 株式会社東芝 | 高周波誘導加熱時外面温度制御方法および当該制御装置 |
| JP2007063642A (ja) | 2005-09-01 | 2007-03-15 | Hitachi Ltd | 残留応力改善方法と高周波誘導加熱用コイル |
| GB0520164D0 (en) * | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
| WO2007089667A1 (en) * | 2006-01-30 | 2007-08-09 | Irm Llc | Compounds and compositions as ppar modulators |
| US7829713B2 (en) | 2006-02-28 | 2010-11-09 | Helicon Therapeutics, Inc. | Therapeutic piperazines |
| WO2008012010A1 (en) * | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| AU2007293653B2 (en) | 2006-09-08 | 2011-02-17 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| CA2672727A1 (en) | 2006-12-21 | 2008-07-03 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| JP2010515750A (ja) * | 2007-01-11 | 2010-05-13 | アラーガン インコーポレイテッド | スフィンゴシン−１−ホスフェート（ｓ１ｐ）受容体アンタゴニスト生物活性を有する６−置換インドール−３−カルボン酸アミド化合物 |
| CA2679980A1 (en) | 2007-03-21 | 2007-09-27 | Epix Pharmaceuticals, Inc. | S1p receptor modulating compounds and use thereof |
| JP2010525016A (ja) | 2007-04-23 | 2010-07-22 | ノバルティス アーゲー | Ｓｌｐ受容体調節活性を有するフタラジンおよびイソキノリン誘導体 |
| WO2009084501A1 (ja) | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
| NZ586399A (en) * | 2008-01-24 | 2011-12-22 | Ucb Pharma Sa | Compounds comprising a cyclobutoxy group |
| CA2712897A1 (en) | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| ES2370378T3 (es) | 2008-01-30 | 2011-12-14 | Cephalon, Inc. | Derivados sustituidos de piperidina espirocíclica como ligandos del receptor de histamina h3. |
| US20090321144A1 (en) | 2008-06-30 | 2009-12-31 | Wyble Kevin J | Protecting an element from excessive surface wear by localized hardening |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| AU2011212476B2 (en) | 2010-02-04 | 2016-03-31 | Laboratorios Del Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
| TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
-
2011
- 2011-07-07 TW TW100124107A patent/TWI522361B/zh not_active IP Right Cessation
- 2011-07-08 RU RU2013105444/04A patent/RU2576660C2/ru active
- 2011-07-08 SG SG2013000997A patent/SG186952A1/en unknown
- 2011-07-08 PE PE2013000026A patent/PE20130592A1/es active IP Right Grant
- 2011-07-08 AU AU2011275755A patent/AU2011275755B2/en not_active Ceased
- 2011-07-08 CN CN201180033957.0A patent/CN103068827B/zh active Active
- 2011-07-08 PH PH1/2013/500004A patent/PH12013500004A1/en unknown
- 2011-07-08 JP JP2013517399A patent/JP5973429B2/ja active Active
- 2011-07-08 ES ES11733645.3T patent/ES2653682T3/es active Active
- 2011-07-08 AR ARP110102455A patent/AR082136A1/es active IP Right Grant
- 2011-07-08 CA CA2804137A patent/CA2804137C/en active Active
- 2011-07-08 BR BR112013000627-7A patent/BR112013000627B1/pt active IP Right Grant
- 2011-07-08 MX MX2013000360A patent/MX2013000360A/es active IP Right Grant
- 2011-07-08 MY MYPI2013000055A patent/MY161229A/en unknown
- 2011-07-08 UY UY0001033496A patent/UY33496A/es unknown
- 2011-07-08 EP EP11733645.3A patent/EP2590980B1/en active Active
- 2011-07-08 KR KR1020137003333A patent/KR101889694B1/ko not_active Expired - Fee Related
- 2011-07-08 NZ NZ605491A patent/NZ605491A/en not_active IP Right Cessation
- 2011-07-08 WO PCT/EP2011/061586 patent/WO2012004373A1/en not_active Ceased
- 2011-07-08 US US13/808,908 patent/US8796262B2/en not_active Ceased
-
2012
- 2012-12-31 IL IL224054A patent/IL224054A/en active IP Right Grant
-
2013
- 2013-01-07 ZA ZA2013/00157A patent/ZA201300157B/en unknown
- 2013-01-08 CL CL2013000069A patent/CL2013000069A1/es unknown
- 2013-01-09 DO DO2013000009A patent/DOP2013000009A/es unknown
- 2013-01-25 CO CO13014079A patent/CO6670577A2/es active IP Right Grant
- 2013-02-04 EC ECSP13012416 patent/ECSP13012416A/es unknown
- 2013-02-08 CR CR20130056A patent/CR20130056A/es unknown
- 2013-09-05 US US14/019,236 patent/US9096612B2/en active Active
-
2015
- 2015-06-18 US US14/743,234 patent/US9670220B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012416A (es) | Derivados heterocíclicos fusionados como moduladores s1p | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR073574A1 (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
| MX2011011875A (es) | Compuesto de carboxamida heterociclica diamino. | |
| AR082135A1 (es) | Derivados de espiro-piperidina como moduladores s1p | |
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR092538A1 (es) | Inhibidores de girasa triciclica | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
| AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| AR081390A1 (es) | Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra) | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| AR089175A1 (es) | Inhibidores de pak para el tratamiento de trastornos de proliferacion celular | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR056445A1 (es) | Derivados arilicos y heteroarilicos de 6 miembros para tratar virus | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |